Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cancer Immunoediting and beyond in 2021
Elena Monica Borroni, Fabio Grizzi
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13275-13275
Open Access | Times Cited: 21

Showing 21 citing articles:

Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers
Alicia Cristina Peña-Romero, Esteban Orenes‐Piñero
Cancers (2022) Vol. 14, Iss. 7, pp. 1681-1681
Open Access | Times Cited: 149
Update in TIGIT Immune-Checkpoint Role in Cancer
Tiziana Annese, Roberto Tamma, Doménico Ribatti
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 32
The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Despoina Eugenia Kiousi, Antonia Z. Kouroutzidou, Konstantinos Neanidis, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2101-2101
Open Access | Times Cited: 21
Intratumor Heterogeneity and Treatment Resistance of Solid Tumors with a Focus on Polyploid/Senescent Giant Cancer Cells (PGCCs)
Razmik Mirzayans, David Murray
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11534-11534
Open Access | Times Cited: 20
Immunotherapy for colorectal cancer: insight from inherited genetics
Nijole P. Tjader, Amanda E. Toland
Trends in cancer (2024) Vol. 10, Iss. 5, pp. 444-456
Closed Access | Times Cited: 6
What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?
Razmik Mirzayans, David Murray
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13217-13217
Open Access | Times Cited: 26
Advancing Cancer Immunotherapy: The Potential of mRNA Vaccines As a Promising Therapeutic Approach
Falak Goyal, Anandini Chattopadhyay, Umashanker Navik, et al.
Advanced Therapeutics (2023) Vol. 7, Iss. 2
Open Access | Times Cited: 8
Recent developments in chemodrug-loaded nanomedicines and their application in combination cancer immunotherapy
Nayeon Shim, Hanhee Cho, Seong Ik Jeon, et al.
Journal of Pharmaceutical Investigation (2023) Vol. 54, Iss. 1, pp. 13-36
Closed Access | Times Cited: 7
Development and validation of nomogram models for predicting postoperative prognosis of early-stage laryngeal squamous cell carcinoma
Juan Xu, Huang JiaLi, Ziqi Liu, et al.
Current Problems in Cancer (2024) Vol. 49, pp. 101079-101079
Closed Access | Times Cited: 2
Cracking the Codes behind Cancer Cells’ Immune Evasion
Nikita Mundhara, Pritam Sadhukhan
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 16, pp. 8899-8899
Open Access | Times Cited: 2
Nano-bio-encapsulation of phyto-vaccines: a breakthrough in targeted cancer immunotherapy
Pavithra Ayyadurai, Chinnasamy Ragavendran
Molecular Biology Reports (2024) Vol. 52, Iss. 1
Closed Access | Times Cited: 2
Sialic acid-modified doxorubicin liposomes target tumor-related immune cells to relieve multiple inhibitions of CD8 + T cells
Zhouchunxiao Du, Dezhi Sui, Dongzhe Xin, et al.
Journal of Liposome Research (2024) Vol. 34, Iss. 3, pp. 464-474
Closed Access | Times Cited: 1
Towards a framework for predicting immunotherapy outcome: a hybrid multiscale mathematical model of immune response to vascular tumor growth
Sayyed Mohammad Ali Mortazavi, Bahar Firoozabadi
Biomechanics and Modeling in Mechanobiology (2024) Vol. 23, Iss. 6, pp. 2243-2264
Closed Access | Times Cited: 1
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
Tannaz Dehghani, Alireza Shahrjerdi, Mohammad Saeed Kahrizi, et al.
Pathology - Research and Practice (2023) Vol. 246, pp. 154470-154470
Closed Access | Times Cited: 3
Response Challenges to Cancer Immunotherapies
Ismail Ibrahim Al-Janabi
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) (2022) Vol. 2, pp. 51-80
Open Access | Times Cited: 5
Glucose metabolism reprogramming promotes immune escape of hepatocellular carcinoma cells
Qiuyue Zhang, Jinchen Liu, Haifeng Lin, et al.
Exploration of Targeted Anti-tumor Therapy (2023), pp. 519-536
Open Access | Times Cited: 2
Microproteins unveiling new dimensions in cancer
Daisy S Precilla, Indrani Biswas, T. S. Anitha, et al.
Functional & Integrative Genomics (2024) Vol. 24, Iss. 5
Closed Access
Immunotherapy to CD5, a T-cell antigen having roles from development to peripheral function: Future prospective and challenges
Ranjeet Bahadur Choubey, Sweta, Vibha Kumari, et al.
Advances in protein chemistry and structural biology (2024), pp. 431-460
Closed Access
Expression of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Oral Squamous Cell Carcinoma and Their Relationship With Clinicopathological Parameters: A Cross-Sectional Study
S Marytresa Jeyapriya, Alok Mohan, M Kumar, et al.
Cureus (2024)
Open Access
Differences in immune response of C57BL/6, В10.D2 (R101) and BALB/c mice to EL-4
А Д Донецкова, М Ф Никонова, N. I. Sharova, et al.
Immunologiya (2022) Vol. 43, Iss. 5, pp. 558-570
Open Access | Times Cited: 1
Immune Compartments and Extracellular Matrix Crosstalk Involved in Tumor Dissemination
Mariana Malvincini, Laura Alaniz
Springer eBooks (2023), pp. 1-22
Closed Access
Page 1

Scroll to top